However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

KdT Ventures has signed off on a $608 million biobucks dea l for NGM Biopharmaceuticals’ phase 2-ready metabolic-dysfunction ...

The FDA is elevating a recall from Boston Scientific covering its cryoablation balloon catheters for the treatment of atrial ...

Omeros is putting up its monoclonal antibody up for FDA approval—again. | Omeros is putting up its monoclonal antibody up for ...

Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 ...

Back-to-back clinical failures have dealt further blows to efforts to treat Parkinson’s disease by targeting alpha-synuclein.

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the ...

After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with a ...

Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies. | Italian VC ...

Flagship CEO-partner and Ring CEO Tuyen Ong, M.D., will also be shifting to an advisory role in the new year, according to ...